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CASE REPORT
Fig. 1. Localized, dusky red colored, centrally umbilicated 
plaque, with a peripheral erythematous patch, on the left foot.
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Cutaneous γ/δ  T-cell lymphoma is an extremely rare and 
highly aggressive tumor that is often resistant to treatment, 
such as polychemotherapy and radiotherapy. Due to the 
complexity of clinical, pathologic, and immunohistoche-
mical features of this disease entity, the physician should 
perform a careful evaluation; however, treatment should be 
rapid and aggressive. We present a case of fatal cutaneous γ/
δ  T-cell lymphoma of a 55-year old woman who died after 
recurrence with central nerve system metastasis. (Ann Der-
matol 23(S1) S100∼S104, 2011)
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INTRODUCTION
Cutaneous gamma/delta (γ/δ) T-cell lymphoma (CGD- 
TCL) is a rare lymphoma recently defined as a provisional 
entity according to the latest World Health Organization 
European Organization for Research and Treatment of 
Cancer (WHO-EORTC) classification. This lymphoma is 
composed of mature cytotoxic T cells bearing the γ/δ 
T-cell receptor. These cells often co-express CD56 and fail 
to express either CD4 or CD8. It shows a refractory 
clinical course.
CASE REPORT
A 56-year-old woman presented at our department with a 
6-week history of localized, dusky red colored, centrally 
umbilicated plaque, with a peripheral erythematous patch 
on the left foot (Fig. 1). Results from laboratory testing 
were within normal limits. A first biopsy of the skin lesion 
revealed epidermal atrophy, dermoepidermal vacuoliza-
tion, massive cellular infiltration of the entire dermis, as 
well as a mostly lobular, inflammatory infiltrate of the sub-
cutaneous fat of lymphoid cells and histiocytes (Fig. 2). At 
high power magnification, the “rimming” of fat cells by 
pleomorphic, atypical T lymphocytes in the subcutaneous 
fat was visible (Fig. 2). Following the suspected clinical Fatal Cutaneous γ/δ T-Cell Lymphoma
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Fig. 2. (A, B) Epidermal atrophy, dermoepidermal vacuolization, massive cellular infiltration of the entire dermis, as well as a mostly 
lobular, inflammatory infiltrate of the subcutaneous fat of lymphoid cells and histiocytes (H&E, ×100). (C, D) At high power magni-
fication, the “rimming” of fat cells by pleomorphic, atypical T lymphocytes in the subcutaneous fat was visible (H&E, ×400).
diagnosis of lymphoma, immunohistochemical stains we-
re performed. Results showed positivity for CD3 (Fig. 3A) 
and Granzyme B, focally positive for CD30, with high 
proliferative activity on Ki-67, and negativity for CD4 (Fig. 
3B), CD8 (Fig. 3C), CD20, CD56, and βF1 (Fig. 3D). 
Monoclonal rearrangement of TCRγ genes was detected. 
All of these findings were consistent with a diagnosis of 
CGD-TCL. After diagnosis, the patient underwent a total of 
4,000 cGy of radiotherapy.
Four months after the first biopsy, the skin lesion recurred 
on the left foot and a single subcutaneous pea-sized no-
dule developed on the left axilla. A new biopsy was taken, 
revealing lymphocytic infiltrates within the superficial and 
deep dermis, and also the subcutis, with a lobular pattern. 
Results of immunohistochemical staining were the same 
as those of the previous biopsy. Based on these findings, 
we made a diagnosis of recurred and metastasized CGD- 
TCL, and administered radiotherapy. One month later, the 
patient underwent magnetic resonance imaging (MRI) for 
evaluation of pain on the right upper extremities, inter-
scapular area, and radiating pain on the right thigh. MRI 
showed metastasis (white arrows) in the spinal cord (Fig. 
4). The patient died of multiple organ failure with CMV 
pneumonia and pancytopenia one month after detection 
of metastasis. 
DISCUSSION
CGD-TCL is a rare sub-type of peripheral cutaneous T-cell 
lymphoma. It is a highly aggressive tumor and is resistant 
to chemotherapy and radiation therapy
1. In 2005, 
CGD-TCL was classified as a provisional entity in the 
WHO-EORTC classification for primary cutaneous 
peripheral T-cell lymphoma
2. Since 2008, CGD-TCL has 
been included in the WHO classification as a rare 
sub-type of primary cutaneous peripheral T-cell 
lymphoma
3. Lesions of this sub-type resemble those of 
panniculitis; therefore, it was previously known as the γ/SH Youn, et al
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Fig. 3. Tumor cells in the dermis were positive for CD3 (A, ×400) and negative for CD4 (B, ×400), CD8 (C, ×400), and βF1 
(D, ×400).
Fig. 4. MRI showed metastasis (white 
arrows) in the spinal cord.
δ  sub-type of subcutaneous panniculitis-like T-cell 
lymphoma (SPTCL)
4,5. Based on cell surface receptors on 
neoplastic T-cells, SPTCL was further subdivided into a α/
β sub-type and a γ/δ sub-type
2,5. Histopathologic fin-
dings, immunohistochemical findings, and prognosis bet-
ween these 2 sub-types showed considerable difference
6. 
Histologically, the α/β sub-type is usually limited to the 
subcutaneous fat; however, the γ/δ sub-type can infil-Fatal Cutaneous γ/δ T-Cell Lymphoma
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trate from the subcutaneous fat to the epidermis
5. On 
immunohistochemical staining, the former usually has a 
CD4−, CD8＋, and CD56− phenotype, whereas the latter 
commonly presents with CD4−, CD8−  and CD56＋
5. 
Willemze et al.
2 studied 83 cases of SPTCL in order to 
investigate differences between the α/β and γ/δ sub- 
types. Results showed development of the γ/δ sub-type 
in older patients, with more frequent ulceration, a more 
progressive disease course, rare positivity of CD8, with 
negativity of βF1, and greater positivity of CD56 (60% vs. 
0%) and TCRδ (100% vs. 0%), compared with the α/β 
sub-type
2. In addition, the γ/δ sub-type SPTCL is more 
commonly associated with hemophagocytic syndrome
7 
(50% vs. 17%) and a worse prognosis (5-y overall survival: 
82% vs. 11%). The median survival of CGD-TCL is 15 
months
6. Owing to these considerable differences, and its 
rapidly fatal course, the γ/δ sub-type of SPTCL has been 
reclassified as CGD-TCL
8. 
Clinical features of CGD-TCL are variable: Lesions present 
as patches, plaques, nodules, or necrotic tumors, which 
are often ulcerated and primarily affect the extremities
9. 
Patients are adults, with an equal distribution of males and 
females, and absence of a history of mycosis fungoides
10. 
Presentation of these clinical features should arouse sus-
picion for the diagnosis of CGD-TCL. Histopathology 
shows proliferation of small/medium to large sized pleo-
morphic lymphocytes, with both marked epidermo-
tropism and involvement of subcutaneous tissues
10. Intrae-
pidermal vesiculation, necrosis, angiocentricity, and ang-
iodestruction can also be present
10. Subcutaneous nodules 
may be panniculitis-like, and may show a rimming of fat 
cells, similar to the SPTCL α/β sub-type
6. On immuno-
histochemical staining, tumor cells have a CD2＋, CD3＋, 
CD4−, CD5−, CD7＋/−, CD8＋/−, CD56＋/− and β
F1-phenotype, with strong expression of cytotoxic pro-
teins, like TIA-1, granzyme B, and perforin. They also 
show high proliferative activity on Ki-67. TCRγ gene 
monoclonal rearrangement can be seen
6,10. Toro et al.
9 
investigated factors affecting survival with cutaneous T-cell 
lymphoma, and showed that the γ/δ sub-type with sub-
cutaneous involvement is predictive of a statistically 
significant decrease in survival
9. Takeshita et al.
11 reported 
that 5-year survival rates for subcutaneous panniculitis-like 
CD56＋ and CD56− lymphoma were 17% and 92%, re-
spectively. Although the study was performed before the 
WHO-EORTC classification was made, it informed that 
CD56＋ is a bad prognostic factor. However, in our case, 
the prognosis was bad in spite of CD56 negativity. This 
discrepancy may be due to factors other than CD56, 
which may be more influential in determining the 
prognosis of CGD-TCL. 
In addition to SPTCL, there are several other cutaneous 
lymphomas that need to be differentiated from CGD-TCL: 
Cutaneous anaplastic large cell lymphoma shows similar 
clinical and histological findings to CGD-TCL; however, it 
is composed of palisading large anaplastic cells, which 
show strong positivity for CD30. Furthermore, it has a 
favorable prognosis
8. Extranodal NK/T cell lymphoma 
nasal type is distinguished by positivity of CD56 and EBV, 
and is encoded as RNA (EBER)
9. Cutaneous small-medium 
pleomorphic T-cell lymphoma consistently shows βF1 
positive results and has smaller pleomorphic cells than 
CGD-TCL
10. Another differential diagnosis with CGD-TCL 
is primary cutaneous aggressive epidermotropic CD8＋ 
cytotoxic T-cell lymphoma, which shows βF1 positive 
tumor cells, and lesser involvement of the subcutaneous 
fat, with a lower presence of interface dermatitis
10. 
Patients with CGD-TCL may follow a protracted course, 
with resistance to currently used chemotherapeutic regi-
mens, such as CHOP (cyclophophamid, doxorubicin, vin-
cristine, and prednisolone) and to radiation therapy, and 
have a poor prognosis
5,10. However, a few cases of treat-
ment of CGD-TCL by allogenic stem cell transplantation 
have been reported, while treatment of CGD-TCL with 
retinoid and narrow band UVB
12 is challenging, and will 
require further study. 
Histological findings showed neoplastic lymphocyte infil-
tration into subcutaneous fat, positivity of CD3 and Gran-
zyme B, proliferative activity of Ki-67, and negativity of 
the CD20 immunoperoxidase stain, although the epider-
motropism was not distinct; therefore, our case was 
initially diagnosed as cutaneous T-cell lymphoma. After 
additional CD30, CD56, CD4, CD8, and βF1 staining, 
we made a diagnosis of CGD-TCL. Despite treatment with 
radiotherapy, recurrence and metastasis to the axillary 
node, spinal cord, and brain were observed within 4 
months. Having failed to respond to treatment, the disease 
showed rapid progress to death by infection and multiple 
organ failure just 6 months after initial diagnosis. We have 
documented herein a rare case of fatal CGD-TCL with 
CNS metastasis as a reminder of the importance of 
suspicion, early diagnosis, and sufficiently aggressive treat-
ment, in order to improve the prognosis.
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